Chemotherapy-resistant intravascular lymphoma accompanied by ADAMTS13 inhibitor successfully treated with rituximab.
Kanno
Masatoshi
M
Tumor Center, Nara Medical University Hospital, 840 Shijo-cho, Kashihara, 634-8522, Japan. mkanno@naramed-u.ac.jp.
Nakamura
Shinobu
S
Department of General Medicine, Nara Medical University, Kashihara, Japan.
Kawahara
Makoto
M
Department of Neurology, Nara Medical University, Kashihara, Japan.
Ueno
Satoshi
S
Department of Neurology, Nara Medical University, Kashihara, Japan.
Nakamine
Hirokazu
H
Department of Diagnostic Pathology, Nara Medical University, Kashihara, Japan.
Matsumoto
Masanori
M
Department of Blood Transfusion Medicine, Nara Medical University, Kashihara, Japan.
Fujimura
Yoshihiro
Y
Department of Blood Transfusion Medicine, Nara Medical University, Kashihara, Japan.
D051722:ADAM Proteins / Q000037:antagonists & inhibitors*; D000071120:ADAMTS13 Protein; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001323:Autoantibodies / Q000097:blood*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D004791:Enzyme Inhibitors / Q000097:blood*; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy* / Q000201:enzymology; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D001323:Autoantibodies; D004791:Enzyme Inhibitors; D000069283:Rituximab; D051722:ADAM Proteins; D000071120:ADAMTS13 Protein; C099604:ADAMTS13 protein, human